
Christopher C Benz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/229178/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer. Breast Cancer Research and Treatment, 2022, 191, 451-458.	2.5	2
2	Clinical and molecular characteristics of estrogen receptorâ€positive ultralow risk breast cancer tumors identified by the 70â€gene signature. International Journal of Cancer, 2022, 150, 2072-2082.	5.1	7
3	Characterization of Benign Breast Diseases and Association With Age, Hormonal Factors, and Family History of Breast Cancer Among Women in Sweden. JAMA Network Open, 2021, 4, e2114716.	5.9	14
4	N-Propargylglycine: a unique suicide inhibitor of proline dehydrogenase with anticancer activity and brain-enhancing mitohormesis properties. Amino Acids, 2021, 53, 1927-1939.	2.7	5
5	Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ <i>ERBB2</i> -Negative Breast Cancer Treated With and Without Tamoxifen Therapy. JAMA Network Open, 2021, 4, e2114904.	5.9	12
6	A risk-associated Active transcriptome phenotype expressed by histologically normal human breast tissue and linked to a pro-tumorigenic adipocyte population. Breast Cancer Research, 2020, 22, 81.	5.0	12
7	Cancer and Cardiovascular Risk in Women With Hypertensive Disorders of Pregnancy Carrying a Common IGF1R Variant. Mayo Clinic Proceedings, 2020, 95, 2684-2696.	3.0	3
8	Pregnancy Hypertension and a Commonly Inherited IGF1R Variant (rs2016347) Reduce Breast Cancer Risk by Enhancing Mammary Gland Involution. Journal of Oncology, 2019, 2019, 1-8.	1.3	6
9	Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition. Molecular Cancer Therapeutics, 2019, 18, 1374-1385.	4.1	26
10	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell, 2018, 173, 400-416.e11.	28.9	2,277
11	Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell, 2018, 173, 371-385.e18.	28.9	1,670
12	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell, 2018, 173, 291-304.e6.	28.9	1,718
13	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell, 2018, 173, 305-320.e10.	28.9	272
14	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell, 2018, 173, 338-354.e15.	28.9	1,417
15	Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell, 2018, 173, 321-337.e10.	28.9	2,111
16	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Reports, 2018, 23, 194-212.e6.	6.4	245
17	Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. Cell Reports, 2018, 23, 213-226.e3.	6.4	83
18	Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype. Scientific Reports, 2018, 8, 2410.	3.3	93

CHRISTOPHER C BENZ

#	Article	IF	CITATIONS
19	Discovery of internalizing antibodies to basal breast cancer cells. Protein Engineering, Design and Selection, 2018, 31, 17-28.	2.1	4
20	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell, 2018, 33, 676-689.e3.	16.8	750
21	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell, 2018, 33, 721-735.e8.	16.8	396
22	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell, 2018, 33, 690-705.e9.	16.8	478
23	Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. Cancer Cell, 2018, 34, 211-224.e6.	16.8	623
24	Functional IGF1R variant predicts breast cancer risk in women with preeclampsia in California Teachers Study. Cancer Causes and Control, 2017, 28, 1027-1032.	1.8	9
25	ERpS294 is a biomarker of ligand or mutational ERÎ \pm activation and a breast cancer target for CDK2 inhibition. Oncotarget, 2017, 8, 83432-83445.	1.8	11
26	DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome Atlas. Npj Breast Cancer, 2016, 2, 16007.	5.2	33
27	<scp>DGCR</scp> 8 is essential for tumor progression following <scp>PTEN</scp> loss in the prostate. EMBO Reports, 2015, 16, 1219-1232.	4.5	9
28	FOXM1 cistrome predicts breast cancer metastatic outcome better than FOXM1 expression levels or tumor proliferation index. Breast Cancer Research and Treatment, 2015, 154, 23-32.	2.5	8
29	Sources of superoxide/H2O2 during mitochondrial proline oxidation. Redox Biology, 2014, 2, 901-909.	9.0	62
30	A steroid metabolizing gene variant in a polyfactorial model improves risk prediction in a high incidence breast cancer population. BBA Clinical, 2014, 2, 94-102.	4.1	4
31	mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms. Breast Cancer Research and Treatment, 2014, 144, 287-298.	2.5	42
32	Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin. Cell, 2014, 158, 929-944.	28.9	1,242
33	First pregnancy events and future breast density: modification by age at first pregnancy and specific VEGF and IGF1R gene variants. Cancer Causes and Control, 2014, 25, 859-868.	1.8	19
34	RPL24: a potential therapeutic target whose depletion or acetylation inhibits polysome assembly and cancer cell growth. Oncotarget, 2014, 5, 5165-5176.	1.8	34
35	Integrated genomic characterization of endometrial carcinoma. Nature, 2013, 497, 67-73.	27.8	4,075
36	An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk. Breast Cancer Research, 2013, 15, R103.	5.0	28

#	Article	IF	CITATIONS
37	PARADIGM-SHIFT predicts the function of mutations in multiple cancers using pathway impact analysis. Bioinformatics, 2012, 28, i640-i646.	4.1	94
38	Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells?. Breast Cancer Research and Treatment, 2012, 136, 693-703.	2.5	15
39	Targeting Molecular Aberrations in Breast Cancer: Is It about Time?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 186-191.	3.8	0
40	Young age, increased tumor proliferation and FOXM1 expression predict early metastatic relapse only for endocrine-dependent breast cancers. Breast Cancer Research and Treatment, 2011, 126, 803-810.	2.5	29
41	Recent trends in hormone therapy utilization and breast cancer incidence rates in the high incidence population of Marin County, California. BMC Public Health, 2010, 10, 228.	2.9	17
42	ErbB2 Trafficking and Degradation Associated with K48 and K63 Polyubiquitination. Cancer Research, 2010, 70, 3709-3717.	0.9	89
43	A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Research, 2010, 12, R85.	5.0	175
44	Protein Acetylation and Histone Deacetylase Expression Associated with Malignant Breast Cancer Progression. Clinical Cancer Research, 2009, 15, 3163-3171.	7.0	110
45	Impact of aging on the biology of breast cancer. Critical Reviews in Oncology/Hematology, 2008, 66, 65-74.	4.4	165
46	Ageing, oxidative stress and cancer: paradigms in parallax. Nature Reviews Cancer, 2008, 8, 875-879.	28.4	249
47	Destabilization of ERBB2 Transcripts by Targeting 3′ Untranslated Region Messenger RNA Associated HuR and Histone Deacetylase-6. Molecular Cancer Research, 2008, 6, 1250-1258.	3.4	54
48	Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers. Breast Cancer Research, 2007, 9, R59.	5.0	64
49	Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer, 2007, 7, 59.	2.6	175
50	Novel Pathways Associated with Quinone-Induced Stress in Breast Cancer Cells. Drug Metabolism Reviews, 2006, 38, 601-613.	3.6	19
51	Altered promoter usage characterizes monoallelic transcription arising withERBB2 amplification in human breast cancers. Genes Chromosomes and Cancer, 2006, 45, 983-994.	2.8	8
52	Breast Cancer Growth Prevention by Statins. Cancer Research, 2006, 66, 8707-8714.	0.9	309
53	Validated High-Throughput Screening of Drug-Like Small Molecules for Inhibitors of ErbB2 Transcription. Assay and Drug Development Technologies, 2006, 4, 273-284.	1.2	12
54	Devious signals from NFκB driving breast cancer progression. Breast Cancer Online: BCO, 2005, 8, .	0.1	0

CHRISTOPHER C BENZ

#	Article	IF	CITATIONS
55	Reactivity of zinc finger cysteines: Chemical modifications within labile zinc fingers in estrogen receptor. Journal of the American Society for Mass Spectrometry, 2005, 16, 2017-2026.	2.8	23
56	Hyperplasia, reduced E-cadherin expression, and developmental arrest in mammary glands oxidatively stressed by loss of mitochondrial superoxide dismutase. Breast, 2005, 14, 256-263.	2.2	13
57	Vitamin K3 (Menadione)-Induced Oncosis Associated with Keratin 8 Phosphorylation and Histone H3 Arylation. Molecular Pharmacology, 2005, 68, 606-615.	2.3	30
58	Activation of nuclear factor-l̂ºB (NFl̂ºB) identifies a high-risk subset of hormone-dependent breast cancers. International Journal of Biochemistry and Cell Biology, 2005, 37, 1130-1144.	2.8	123
59	Essential cysteine-alkylation strategies to monitor structurally altered estrogen receptor as found in oxidant-stressed breast cancers. Analytical Biochemistry, 2003, 320, 21-31.	2.4	13
60	Geographic excess of estrogen receptor-positive breast cancer. Cancer Epidemiology Biomarkers and Prevention, 2003, 12, 1523-7.	2.5	5
61	Redox Control of Zinc Finger Proteins. Methods in Enzymology, 2002, 353, 54-69.	1.0	31
62	Age-associated biomarker profiles of human breast cancer. International Journal of Biochemistry and Cell Biology, 2002, 34, 1318-1330.	2.8	90
63	ErbB2 Activation of ESX gene expression. Oncogene, 2002, 21, 3934-3938.	5.9	35
64	Age-Dependent Changes in Breast Cancer Hormone Receptors and Oxidant Stress Markers. Breast Cancer Research and Treatment, 2002, 76, 221-236.	2.5	60
65	Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen. Molecular Cancer Therapeutics, 2002, 1, 385-92.	4.1	44
66	Prognostic and Predictive Significance of ErbB-2 Breast Tumor Levels Measured by Enzyme Immunoassay. Journal of Clinical Oncology, 2001, 19, 645-656.	1.6	85
67	Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation. Oncogene, 2001, 20, 2101-2111.	5.9	53
68	Ets regulation of the erbB2 promoter. Oncogene, 2000, 19, 6490-6502.	5.9	68
69	A Role for Both Ets and C/EBP Transcription Factors and mRNA Stabilization in the MAPK-dependent Increase in p21 ^{Cip-1/WAF1/mda6} Protein Levels in Primary Hepatocytes. Molecular Biology of the Cell, 2000, 11, 2915-2932.	2.1	73
70	Preferential Oxidation of Zinc Finger 2 in Estrogen Receptor DNA-binding Domain Prevents Dimerization and, Hence, DNA Bindingâ€. Biochemistry, 2000, 39, 8406-8417.	2.5	57
71	Tyrosine Kinase Inhibitors Targeted to the Epidermal Growth Factor Receptor Subfamily. Drugs, 2000, 59, 753-767.	10.9	152
72	Exon 4-encoded acidic domain in the epithelium-restricted Ets factor, ESX, confers potent transactivating capacity and binds to TATA-binding protein (TBP). Oncogene, 1999, 18, 3682-3695.	5.9	26

CHRISTOPHER C BENZ

#	Article	IF	CITATIONS
73	Polyamine inhibition of estrogen receptor (ER) DNA-binding and ligand-binding functions. Breast Cancer Research and Treatment, 1998, 48, 243-257.	2.5	19
74	Oxidant stress impaired DNA-binding of estrogen receptor from human breast cancer. Molecular and Cellular Endocrinology, 1998, 146, 151-161.	3.2	55
75	Targeting of Drugs to Solid Tumors Using Anti-Her2 Immunoliposomes. Journal of Liposome Research, 1998, 8, 425-442.	3.3	19
76	Targeting of Liposomes to Solid Tumors: The Case of Sterically Stabilized Anti-Her2 Immunoliposomes. Journal of Liposome Research, 1997, 7, 391-417.	3.3	28
77	ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis. Oncogene, 1997, 14, 1617-1622.	5.9	159
78	HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene, 1997, 15, 1513-1525.	5.9	147
79	Oxidant-sensitive protein phosphorylation in endothelial cells. Free Radical Biology and Medicine, 1994, 16, 771-777.	2.9	32
80	Tumor labeling indices of primary breast cancers and their regional lymph node metastases. Cancer, 1993, 71, 3914-3919.	4.1	22
81	Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Research and Treatment, 1992, 24, 85-95.	2.5	670
82	Stress Response Protein (srp-27) Determination in Primary Human Breast Carcinomas: Clinical, Histologic, and Prognostic Correlations. Journal of the National Cancer Institute, 1991, 83, 170-178.	6.3	150
83	Clinical Pharmacokinetics of Drugs Used in the Treatment of Breast Cancer. Clinical Pharmacokinetics 1988 15 180-193	3.5	14